Predictive value and accuracy of [¹⁸F]FDG PET/CT modified response criteria for checkpoint immunotherapy in patients with advanced melanoma.

ABSTRACT:

Purpose

Immune checkpoint inhibitors (ICIs) are widely used in metastatic melanoma and dramatically alter the treatment of these patients. Given the high cost and potential toxicity, a reliable method for evaluating treatment response is needed. In this study, we assessed tumor response in patients with metastatic melanoma treated with ICIs using three modified response criteria: PET Response Evaluation Criteria for Immunotherapy (PERCIMT), PET Response Criteria in Solid Tumors for up to Five Lesions (PERCIST5), and immunotherapy-modified PET Response Criteria in Solid Tumors for up to Five Lesions (imPERCIST5).

Methods

Ninety-one patients with non-resectable stage IV metastatic melanoma who received ICIs were retrospectively enrolled in this study. Each patient had two [

SUBMITTER: Ayati N 

PROVIDER: S-EPMC10317870 | biostudies-literature | 2023 Jul

REPOSITORIES: biostudies-literature